Home › Interstitial Lung Diseases › Virginia
Interstitial Lung Diseases clinical trials in Virginia
8 studies for Interstitial Lung Diseases are looking for participants at sites in Virginia.
Cities in Virginia
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- USA008, Richmond
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07179380A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Virginia Commonwealth University, Richmond
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 8, 2026 · NCT07201922Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- Virginia Commonwealth University, Richmond
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06911632DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Inova Medical Group, Falls Church
- Sentara Norfolk General Hospital, Norfolk
- Pulmonary Associates of Richmond, Inc., Richmond
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06388421PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
- University of Virginia, Charlottesville
RecruitingObservational study
Ages 18 to 80 · All sexes · Updated Aug 18, 2026 · NCT06855329Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Inova, Falls Church
RecruitingObservational study
Ages 21 and older · All sexes · Updated Aug 12, 2026 · NCT01915511Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- University of Virginia Health System, Charlottesville
- Christopher King, MD, Falls Church
- Pulmonary Associates of Richmond, Inc., Richmond
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05943535Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 7, 2025 · NCT05892614From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.